RESTRICTED AREA
* The information contained on this page is intended for veterinarians or animal health professionals with the ability to prescribe and/or dispense medicines.If you meet these requirements, talk to our sales department.
Ref.: 578612
PROTEQ WEST NILE 2DS
West Nile Virus
If you have already registered, log in to GirovetPro
Description
PHARMACEUTICAL FORM
Injectable suspension. Homogeneous opalescent suspension.
SPECIES
Horses.
Injectable suspension. Homogeneous opalescent suspension.
SPECIES
Horses.
Indications
For active immunization of horses from 5 months of age against West Nile disease by reducing the number of viremic horses. If clinical signs are manifested, their duration and severity are reduced.
- Establishment of immunity: 4 weeks after the first dose of the primary vaccination. To achieve full protection, the two-dose schedule program should be followed.
- Duration of immunity: 1 year after the complete primary vaccination with two injections.
- Establishment of immunity: 4 weeks after the first dose of the primary vaccination. To achieve full protection, the two-dose schedule program should be followed.
- Duration of immunity: 1 year after the complete primary vaccination with two injections.
Dose / Application / Administration
Route of administration:
Intramuscular.
Dosage:
Administer 1 dose of 1ml by intramuscular injection, preferably in the neck, according to the following schedule:
Intramuscular.
Dosage:
Administer 1 dose of 1ml by intramuscular injection, preferably in the neck, according to the following schedule:
- Primary vaccination: first injection at 5 months of age; second injection after 4 – 6 weeks.
- Booster injection: a sufficient degree of protection after the annual booster injection with a single 1ml dose, although this schedule has not been fully validated.
It can be used during pregnancy and lactation.
Composition
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1ml contains:
Active substance:
Recombinant canaripox virus West Nile (vCP2017): 6,0 a 7,8 log10 DICC*50
*Infectious dose 50% cell culture
Adjuvant:
Carbomer: 4mg
Each dose of 1ml contains:
Active substance:
Recombinant canaripox virus West Nile (vCP2017): 6,0 a 7,8 log10 DICC*50
*Infectious dose 50% cell culture
Adjuvant:
Carbomer: 4mg
Presentation
2 vials with 1 dose
Laboratory
BOEHRINGER
Leave us your comment